PT  - JOURNAL ARTICLE
AU  - Paul, Kimberly C
AU  - Zhang, Keren
AU  - Walker, Douglas I
AU  - Sinsheimer, Janet
AU  - Yu, Yu
AU  - Kusters, Cynthia
AU  - Rosario, Irish Del
AU  - Folle, Aline Duarte
AU  - Keener, Adrienne M
AU  - Bronstein, Jeff
AU  - Jones, Dean P
AU  - Ritz, Beate
TI  - Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease
AID  - 10.1101/2022.12.29.22284028
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.29.22284028
4099  - http://medrxiv.org/content/early/2022/12/30/2022.12.29.22284028.short
4100  - http://medrxiv.org/content/early/2022/12/30/2022.12.29.22284028.full
AB  - Objectives Recent advances in high-resolution metabolomics platforms allow the simultaneous measurement of thousands of small molecules produced from metabolism (metabolites), providing a map of disease-related perturbations across interconnected pathways. We used high performance, untargeted metabolomics to identify metabolic disturbances and molecular events associated with Parkinson’s disease (PD) in two population-based studies.Methods We performed a metabolome-wide association study (MWAS) on PD, using serum-based untargeted metabolomics data derived from high resolution liquid chromatography, mass spectrometry (LCMS). We used two independent, case-control populations for discovery and replication (n=642 PD patients, n=277 controls).Results From the LCMS, 5,145 metabolites were detected across the two study populations in ≥50% of the samples (HILIC: 2913 metabolites; C18: 2063 metabolites). Using logistic regression and an FDR to correct for multiple testing, we determined 236 metabolites were associated with PD in a meta-analysis at an FDR<0.05. Of these, 110 metabolites were independently associated with PD in both discovery and replication studies at p<0.05 (187 at p<0.10), while 24 were associated with levodopa-equivalent dose among the PD patients. Intriguingly, the microbial related metabolite, p-cresol (meta-OR=1.29, 95% CI=1.13, 1.47, FDR=0.01), and it’s two metabolites, p-cresol sulfate and p-cresol glucuronide, were found at higher intensity among the PD patients relative to controls. P-cresol glucuronide was also associated with motor symptoms among patients. Pyroglutamic acid (meta OR=3.79, 95% CI=2.60, 5.54; FDR=5.30E-09), the anti-inflammatory metabolite itaconate (meta OR=0.47, 95% CI=0.36, 0.61; FDR=8.44E-06), and cysteine-S-sulfate (meta OR=1.56, 95% CI=1.32, 1.83; FDR=1.66E-05) were also among the most strongly associated metabolites. Seventeen pathways were also enriched, including several related to amino acid and lipid metabolism.Conclusions Our results revealed PD-associated metabolites in two independent study populations, implicating individual metabolites including p-cresol and itaconate, as well as suggesting metabolic disturbances in amino acid and lipid metabolism and inflammatory processes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institute on Aging (K01AG07204401), National Institute of Environmental Health Sciences (grant number R21ES032593, 2R01ES010544, R21ES024356, R00ES028743, 5P30ES019776)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of The University of California, Los Angeles gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study are available upon reasonable request to the authors